Trial intelligence / Profile preview

Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly

NCT02236052Phase 2Completed

Sponsor
Medicago Inc.
Start
Jul 2014
Primary completion
Jun 2015
Countries
1
01

Overview

Phase 2, randomised, single-blind trial in influenza, sponsored by Medicago Inc. Primary endpoints: Immunogenicity at 21 days and Solicited systemic and local reactions at 21 days. Started Jul 2014; status: completed.

02

Conditions

influenza

Beyond the preview

Go deeper on NCT02236052.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02236052.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call